Chemring Group shares gained after its Roke subsidiary signed a multi-year partnering agreement worth at least $170m with a major US prime contractor for miniature radar altimeters.

Chemring Group PLC (LSE:CHG), the defence technology and energetics specialist, attracted fresh buying interest this week after announcing a significant new agreement in the United States. On Wednesday, 14 October 2026, the company said its Roke business had signed a strategic partnering agreement with an unnamed major US prime contractor, worth at least $170m over the first five years. The shares rose more than 3% in morning trading to around 515.5p and extended their gains on Thursday, closing at 520p, up about 1.6% on the day.

Details of the Roke agreement

The deal covers the supply of Roke's Nav-Sync miniature radar altimeter, a commercial off-the-shelf product that Chemring (LSE:CHG) describes as the smallest and lightest radar altimeter of its type for high-speed platforms and uncrewed air vehicles. Radar altimeters measure height above the ground and are used in navigation and guidance systems, an area of growing demand as militaries invest heavily in drones and precision munitions.

After the initial five-year period, the agreement is expected to run until at least 2035. Roke has already received a first production order worth $16m, covering the first 12 months, with deliveries beginning in October 2026.

Chief executive Michael Ord said the deal marked a milestone in Roke's strategy to grow revenue from its defence products. He also noted that Roke is making progress internationally despite near-term headwinds in its domestic defence market, a reference to the slower pace of contract awards in the UK while the government finalises its defence investment plans.

Solid order book, mixed year

The announcement comes as Chemring approaches the end of its financial year on 31 October. The company began the year more slowly than expected, citing operational disruption in countermeasures production, which management later said had largely been resolved. Its order book stood at a record of around £1.36bn at the end of January, and the board has consistently said that its outlook for the year is in line with expectations, with revenue more heavily weighted to the second half than in the previous year.

Chemring has been investing significantly in additional energetics capacity to meet high demand from NATO and allied governments for propellants, explosives and countermeasures. That investment is being funded from existing debt facilities, and the company has warned that net debt will rise as a result. Defence stocks across Europe have been supported by commitments from NATO members to increase spending, although the timing of individual contracts can make results uneven from one period to the next.

The wider aerospace and defence sector also traded higher on Thursday, providing a supportive backdrop for the shares. Chemring operates through two main segments: Sensors and Information, which includes Roke as well as its chemical and biological detection businesses, and Countermeasures and Energetics, which produces flares, propellants and other energetic materials. The Roke contract is a reminder that the technology-led side of the group can win sizeable product orders as well as services work, which is regarded as an important diversification for the business.

Investors will now look to Chemring's year-end trading commentary and full-year results for confirmation that second-half delivery has met expectations and for an update on the order book and the progress of its energetics expansion.

The Roke agreement adds a meaningful, multi-year revenue stream in the US, a market where the group already has a substantial presence through its countermeasures and sensors businesses.